<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1000" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="421" end="424"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="496" end="499"/>
    <type:OSMean xmi:id="21" sofa="6" begin="504" end="514"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas&#13;&#10;(STSs), the efficacy of chemotherapy in this group is largely unclear, partly&#13;&#10;because older studies are contaminated with gastrointestinal stromal tumors&#13;&#10;(GISTs). In this retrospective study we investigated the outcome of first line&#13;&#10;chemotherapy in 65 patients with unresectable or metastatic LMS. The overall&#13;&#10;response rate (ORR) was 18%; and the median progression-free (PFS) and overall&#13;&#10;survival (OS) were 3.8 and 9.7 months respectively. No statistically significant &#13;&#10;differences in outcomes for uterine and non-uterine LMS were found. In&#13;&#10;non-uterine LMS, however, the PFS and OS seemed to be longer for females than for&#13;&#10;males, potentially negatively affecting outcomes in this group. If our&#13;&#10;observations are confirmed in other series, they would suggest that studies&#13;&#10;performed in STS patients should not only stratify for histological subtype but&#13;&#10;also for uterine versus non-uterine LMS and for gender."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
